Research Focus
Using gene transfer, RNA interference, and gene knockout technologies, we are investigating the metabolic pathways and molecular mechanisms affecting antitumor activity and tumor selectivity of cytotoxic agents, fluoropyrimidines and anthracyclines. For clinical translation, we are exploring rapid, easy methods to monitor the activity of the metabolic pathways and effectors of fluoropyrimidines and anthracyclines. As a final goal, our research will provide evidence and methodologies for the individualization of these chemotherapeutic agents. Using these gene-targeting technologies, we are also investigating the biological function of human aldose reductase-like-1 (AKR1B10) and its role in cancer development and therapy.
Patents
ARL-1 SPECIFIC ANTIBODY (U.S. Application #: 12/032327; Patent #: 8114604，02/14/2012)
METHODS FOR DIAGNOSING BOWEL DISEASE (U.S. Application #: 12/739371, 10/24/2008; Pub. No: US 2010/0256009 A1, 10/07/2010
ARL-1 SPECIFIC ANTIBODIES AND USES THEREOF (U.S. Application #: 13/017618，01/31/2011; Pub. No: US 2011/0195411 A1, 08/11/2011)
Hot Topic Issue
Anti-Lipogenesis as a Novel Strategy for Cancer Therapy. Recent Patents on Anti-Cancer Drug Discovery (Anticancer Drug Discov). 7(2), 2012
Selected Publications
Cao, D., Leffert, J. J. McCabe, J., Kim, B., and Pizzorno, G. Abnormalities in uridine homeostatic regulation and pyrimidine nucleotide metabolism as a consequence of the deletion of the uridine phosphorylase gene. J. Biol. Chem. 280: 21169-21175, 2005
Wan, L., Cao, D., Zeng, J., Yan, R., Pizzorno, G. Modulation of uridine phosphorylase gene expression by tumor necrosis factor-{alpha} enhances the antiproliferative activity of the capecitabine intermediate 5'-deoxy-5-fluorouridine in breast cancer cells. Mol. Pharmacol. 69: 1389-1395, 2006
Zu, X., Yan, R., Robbins, S., Krishack, P., and *Cao, D. Reduced 293T cell susceptibility to acrolein due to aldose reductase-like-1 protein expression. Toxicol. Sci. 97:562-568, 2007
Yan, R., Zu, X., Ma, J. Liu, Z., Adeyanju, M., Liao, D. and *Cao, D. Aldo-keto reductase family 1B10 gene silencing results in growth inhibition of colorectal cancer cell: Implication for cancer intervention. Int. J. Cancer. 121: 2301-2306, 2007
Ma, J., Yan, R., Zu, X., Cheng, J.M., Rao K., Liao, D.F., and *Cao, D. Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells. J. Biol. Chem. 283(6):3418-3423, 2008
Liu, Z., Zhong, L., Krishack, P.A., Robbins, S., Cao, J.X., Zhao, Y., Chung, S.S., and *Cao, D. Structure and promoter characterization of aldo-keto reductase family 1 B10 gene. Gene. 437(1-2):39-44, 2009
Wang C, Liao DL, and *Cao. Acetyl-CoA carboxylase-α inhibitor TOFA induces lung cancer cell apoptosis. Biochem. Biophys. Res. Commun. 385(3):302-306, 2009
Zhong L, Liu Z, Yan R, Johnson S, Fang X, and *Cao D. Aldo-Keto reductase family 1 B10 protein detoxifies alpha, beta-unsaturated carbonyls at physiological levels. Biochem. Biophys. Res. Commun. 2009 Jun 27. [Epub ahead of print]
Wang C, Yan R, Luo D, Watabe, K, Liao DL, and *Cao D. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J. Biol. Chem. 2009 Jul 30. [Epub ahead of print]
Liu J, Wen G, * Cao D. Aldo-Keto Reductase Family 1 B1 Inhibitors: Old Drugs with New Perspectives. Recent Pat Anticancer Drug Discov. 2009 Nov 1. [epub ahead of print] |
